@article{afce90491cc346b79d1998c354f0f5cf,
title = "Sensor-based gait analysis in atypical parkinsonian disorders",
abstract = "Background and Objectives: Gait impairment and reduced mobility are typical features of idiopathic Parkinson's disease (iPD) and atypical parkinsonian disorders (APD). Quantitative gait assessment may have value in the diagnostic workup of parkinsonian patients and as endpoint in clinical trials. The study aimed to identify quantitative gait parameter differences in iPD and APD patients using sensor-based gait analysis and to correlate gait parameters with clinical rating scales. Subjects and Methods: Patients with iPD and APD including Parkinson variant multiple system atrophy and progressive supranuclear palsy matched for age, gender, and Hoehn and Yahr (≤3) were recruited at two Movement Disorder Units and assessed using standardized clinical rating scales (MDS-UPDRS-3, UMSARS, PSP-RS). Gait analysis consisted of inertial sensor units laterally attached to shoes, generating as objective targets spatiotemporal gait parameters from 4 × 10 m walk tests. Results: Objective sensor-based gait analysis showed that gait speed and stride length were markedly reduced in APD compared to iPD patients. Moreover, clinical ratings significantly correlated with gait speed and stride length in APD patients. Conclusion: Our findings suggest that patients with APD had more severely impaired gait parameters than iPD patients despite similar disease severity. Instrumented gait analysis provides complementary rater independent, quantitative parameters that can be exploited for clinical trials and care.",
keywords = "atypical parkinsonian disorders, multiple system atrophy, parkinson's disease, progressive supranuclear palsy, sensor-based gait analysis",
author = "Cecilia Raccagni and Heiko Ga{\ss}ner and Sabine Eschlboeck and Sylvia Boesch and Florian Krismer and Klaus Seppi and Werner Poewe and Eskofier, {Bjoern M.} and Juergen Winkler and Gregor Wenning and Jochen Klucken",
note = "Funding Information: Bavarian State Ministry for Education, Science and the Arts, Munich, Germany (MotionLab@Home, E|Home Center). Emerging Fields Initiative of the Friedrich-Alexander University Erlangen-Nuernberg, Germany (EFI Moves, 2 Med 03). Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Germany (Medical Valley Award 2016, Risk-e-Gait). European Institute of Innovation and Technology Health (EIT Health, {\textquoteleft}MoveIT{\textquoteright}). German Research Foundation (DFG), Germany, Heisenberg professorship programme (grant number ES 434/8-1). German Research Foundation (DFG) and Friedrich-Alexander University Erlangen-Nuernberg (Open Access Publishing). The Multiple System Atrophy Coalition, Inc. (Grant No. 2015-04-003 and 2016-09-008) Funding Information: Eskofier, Jochen Klucken, and Juergen Winkler received institutional research grants from the Emerging Field Initiative of the Friedrich Alexander-University Erlangen-N{\"u}rnberg (EFI Moves, 2 Med 03), from the Bavarian State Ministry for Education, Science and the Arts, Munich, Germany (MotionLab@Home, E|Home Center), from the Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Germany (Medical Valley Award 2016, Risk-e-Gait), and from the European Institute of Innovation and Technology (EIT Health, “MoveIT”). Sabine Eschlb{\"o}ck declares no conflict of interest. Sylvia B{\"o}sch reports grants from European Friedreich Ataxia Consortium for Translational Studies (EFACTS), FP7 Health (HEALTH-F2-2010-242193), fees from serving on scientific advisory boards for Gr{\"u}nenthal, and Abbvie GmbH as well as honoraria from Ipsen, Allergan, Abbvie, Novartis, and Licher. Florian Krismer has received a research grant from the MSA Coalition, travel grants from the Austrian Parkinson{\textquoteright}s disease society as well as the International Parkinson{\textquoteright}s disease and movement disorders Society and nonfinancial support from Fight MSA and Astra-Zeneca, outside the submitted work. Klaus Seppi reports grants from Medical University Innsbruck, grants from Oesterreichische Nationalbank Nationalbank (Austrian Central Bank, Anniversary Fund; project no.: 14174), grants from Austrian Science Fund (FWF: Der Wissenschaftsfonds; project no.: KLI82-B00), grants from the Michael J. Fox Foundation (project: PPMI study), personal fees from International Parkinson and the Movement Disorder Society, personal fees from Teva, personal fees from UCB, personal fees from Lundbeck, personal fees from AOP Orphan, personal fees from Roche and personal fees from Abbvie outside the submitted work. Werner Poewe reports personal fees from AbbVie, AstraZeneca, BIAL, Biogen, Britannia, Gr{\"u}nenthal, Intec, Ipsen, Lundbeck, Novartis, Neuroderm, Orion Pharma, Prexton, Sunovion, Teva, UCB and Zambon. (consultancy and lecture fees in relation to clinical drug development programmes for PD) outside the submitted work. Bjoern Eskofier holds ownerships of Portabiles HealthCare Technologies GmbH and Portabiles GmbH, received compensation and honoraria from serving on scientific advisory boards for Abbvie GmbH, Adidas GmbH, Bosch Sensortec GmbH, and ST Sportservice GmbH. Further, he gratefully acknowledges the support of the German Research Foundation (DFG) within the framework of the Heisenberg professorship programme (grant number ES 434/8-1). J{\"u}rgen Winkler reports personal fees outside of the submitted work from Teva GmbH, Ever Pharma GmbH, Desitin Arzneimittel GmbH, Abbvie GmbH & Co. KG, Biogen GmbH, and GlaxoSmithKline GmbH & Co. KG. Gregor Wenning reports receiving consulting and/or lecture fees from Affiris, Astra Zeneca, Boehringer Ingelheim, Ever Pharma, Lundbeck, Neuropore, Orion and UCB as well as grant support from Medical University Innsbruck, Oesterreichische Nationalbank, FWF Austrian Science Fund, US MSA Coalition, Affiris, Astra Zeneca and Boehringer Ingelheim. Jochen Klucken holds ownerships of Portabiles HealthCare Technologies GmbH and Portabiles GmbH, received compensation and honoraria from serving on scientific advisory boards for LicherMT GmbH, Abbvie GmbH, UCB Pharma GmbH, GlaxoSmithKline GmbH & Co. KG, Athenion GmbH, and Thomashilfen GmbH; as well as lecturing from UCB Pharma GmbH, TEVA Pharma GmbH, Licher MT GmbH, Desitin GmbH, Abbvie GmbH, Solvay Pharmaceuticals, and Ever Neuro Pharma GmbH. Funding Information: Funding information Bavarian State Ministry for Education, Science and the Arts, Munich, Germany (MotionLab@Home, E|Home Center). Emerging Fields Initiative of the Friedrich-Alexander University Erlangen-Nuernberg, Germany (EFI Moves, 2 Med 03). Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Germany (Medical Valley Award 2016, Risk-e-Gait). European Institute of Innovation and Technology Health (EIT Health, ?MoveIT?). German Research Foundation (DFG), Germany, Heisenberg professorship programme (grant number ES 434/8-1). German Research Foundation (DFG) and Friedrich-Alexander University Erlangen-Nuernberg (Open Access Publishing). The Multiple System Atrophy Coalition, Inc. (Grant No. 2015-04-003 and 2016-09-008) We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universit?t Erlangen-N?rnberg (FAU) within the funding program Open Access Publishing. Publisher Copyright: {\textcopyright} 2018 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.",
year = "2018",
month = jun,
doi = "10.1002/brb3.977",
language = "English",
volume = "8",
journal = "Brain and Behavior",
issn = "2157-9032",
publisher = "John Wiley & Sons Inc.",
number = "6",
}